127 related articles for article (PubMed ID: 20177014)
1. Inflammatory pathogenesis of prostate cancer and celecoxib.
Mathew P
J Clin Oncol; 2010 Apr; 28(12):e197; author reply e198. PubMed ID: 20177014
[No Abstract] [Full Text] [Related]
2. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
3. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
4. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
6. PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases.
Sonpavde G; Hayes TG
Mayo Clin Proc; 2005 Aug; 80(8):1100-1. PubMed ID: 16092593
[No Abstract] [Full Text] [Related]
7. [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene].
Wang R; Ciren YJ; Yang JL; Zhang B; Chen JP; Tang CW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 40(6):1029-32. PubMed ID: 20067113
[TBL] [Abstract][Full Text] [Related]
8. The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Heath EI; DeWeese TL; Partin AW; De Marzo AM; Groopman JD; Nelson WG; Piantadosi SA; Lieberman R; Carducci MA
Clin Prostate Cancer; 2002 Dec; 1(3):182-7. PubMed ID: 15046694
[No Abstract] [Full Text] [Related]
9. Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
DuBois RN
J Clin Oncol; 2006 Jun; 24(18):2691-3. PubMed ID: 16782907
[No Abstract] [Full Text] [Related]
10. [Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues].
Ran JT; Zhou YN; Tang CW; Li HH; Li XW; Lu H
Ai Zheng; 2009 Apr; 28(4):361-5. PubMed ID: 19622294
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism.
Bastos-Pereira AL; Lugarini D; Oliveira-Christoff Ad; Ávila TV; Teixeira S; Pires Ado R; Muscará MN; Cadena SM; Donatti L; Cristina da Silva de Assis H; Acco A
Cancer Chemother Pharmacol; 2010 Jan; 65(2):267-76. PubMed ID: 19506872
[TBL] [Abstract][Full Text] [Related]
12. COX-2 inhibitors in prostate cancer treatment--hold your horses?
Cheung AS; Grossmann M
Asian J Androl; 2012 Jul; 14(4):518-9. PubMed ID: 22635163
[No Abstract] [Full Text] [Related]
13. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Garcia M; Velez R; Romagosa C; Majem B; Pedrola N; Olivan M; Rigau M; Guiu M; Gomis RR; Morote J; Reventós J; Doll A
BJU Int; 2014 May; 113(5b):E164-77. PubMed ID: 24127882
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
Sooriakumaran P; Coley HM; Fox SB; Macanas-Pirard P; Lovell DP; Henderson A; Eden CG; Miller PD; Langley SE; Laing RW
Anticancer Res; 2009 May; 29(5):1483-8. PubMed ID: 19443354
[TBL] [Abstract][Full Text] [Related]
15. [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].
Ran JT; Zhou YN; Tang CW; Lu JR; Wu J; Lu H; Yang GD
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):448-51. PubMed ID: 19024521
[TBL] [Abstract][Full Text] [Related]
16. Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Backhus LM; Sievers E; Lin GY; Castanos R; Bart RD; Starnes VA; Bremner RM
J Thorac Cardiovasc Surg; 2006 Aug; 132(2):297-303. PubMed ID: 16872953
[TBL] [Abstract][Full Text] [Related]
17. Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel.
Chen S; Bartick T
J Am Vet Med Assoc; 2006 Jan; 228(1):69-73. PubMed ID: 16426169
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Backhus LM; Petasis NA; Uddin J; Schönthal AH; Bart RD; Lin Y; Starnes VA; Bremner RM
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1406-12. PubMed ID: 16256796
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer chemotherapy in the era of targeted therapy.
Michael A; Syrigos K; Pandha H
Prostate Cancer Prostatic Dis; 2009; 12(1):13-6. PubMed ID: 18521103
[TBL] [Abstract][Full Text] [Related]
20. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
